Penumbra/$PEN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Penumbra
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.
Ticker
$PEN
Sector
Primary listing
NYSE
Employees
4,500
Headquarters
Website
Penumbra Metrics
BasicAdvanced
$10B
69.92
$3.74
0.40
-
Price and volume
Market cap
$10B
Beta
0.4
52-week high
$310.00
52-week low
$192.54
Average daily volume
424K
Financial strength
Current ratio
6.754
Quick ratio
3.804
Long term debt to equity
15.864
Total debt to equity
17.043
Interest coverage (TTM)
121.40%
Profitability
EBITDA (TTM)
210.237
Gross margin (TTM)
69.08%
Net profit margin (TTM)
11.54%
Operating margin (TTM)
15.05%
Effective tax rate (TTM)
14.76%
Revenue per employee (TTM)
$280,000
Management effectiveness
Return on assets (TTM)
7.50%
Return on equity (TTM)
12.03%
Valuation
Price to earnings (TTM)
69.916
Price to revenue (TTM)
7.883
Price to book
7.87
Price to tangible book (TTM)
9.09
Price to free cash flow (TTM)
62.436
Free cash flow yield (TTM)
1.60%
Free cash flow per share (TTM)
4.187
Growth
Revenue change (TTM)
12.92%
Earnings per share change (TTM)
916.05%
3-year revenue growth (CAGR)
16.66%
10-year revenue growth (CAGR)
23.99%
3-year earnings per share growth (CAGR)
92.78%
10-year earnings per share growth (CAGR)
30.96%
What the Analysts think about Penumbra
Analyst ratings (Buy, Hold, Sell) for Penumbra stock.
Bulls say / Bears say
Penumbra reported second-quarter revenue of $339.5 million, up 13.4% year-over-year and above the $327.8 million consensus, driven by U.S. thrombectomy growth of 22.6% and VTE growth of 42%; management raised full-year 2025 revenue guidance to $1.355–1.37 billion. (Investing.com)
In the first quarter of 2025, Penumbra delivered $324.1 million in revenue, a 16.3% increase year-over-year that outpaced projections, with U.S. thrombectomy sales surging 25% and adjusted EPS of $0.83 beating forecasts of $0.67. (Investing.com)
Penumbra expanded its gross margin to 66.0% in Q2 2025, a 1.6 percentage-point improvement over the prior quarter and an 11.6 percentage-point gain year-over-year, reflecting favorable product mix and productivity improvements. (Investing.com)
International revenue declined 3.2% year-over-year in Q2 2025 (5.8% in constant currency), with Chinese market headwinds offsetting growth elsewhere and pressuring Penumbra’s global expansion. (Investing.com)
Full-year revenue guidance of $1.355–1.37 billion reaffirmed in Q2 remains below analysts’ consensus of $1.543 billion, suggesting limited upside relative to market expectations. (Investing.com)
With 76.8% of sales generated in the U.S., Penumbra’s revenue concentration exposes it to U.S. reimbursement policy changes and intensifying domestic competition. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 3 Oct 2025.
Penumbra Financial Performance
Revenues and expenses
Penumbra Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Penumbra stock?
Penumbra (PEN) has a market cap of $10B as of October 10, 2025.
What is the P/E ratio for Penumbra stock?
The price to earnings (P/E) ratio for Penumbra (PEN) stock is 69.92 as of October 10, 2025.
Does Penumbra stock pay dividends?
No, Penumbra (PEN) stock does not pay dividends to its shareholders as of October 10, 2025.
When is the next Penumbra dividend payment date?
Penumbra (PEN) stock does not pay dividends to its shareholders.
What is the beta indicator for Penumbra?
Penumbra (PEN) has a beta rating of 0.4. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.